Download the 2026 Economic Impact Report
Join Now
Join Now

Afaxys Announces Planned Retirement of CEO Ronda Dean and Appointment of Christian Bloomgren to President and CEO

CHARLESTON, S.C., October 13, 2025 – Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals and their patients, today announced the retirement of Ronda Dean, Chief Executive Officer (CEO) & Co-Founder effective January 2, 2026. At that time, Christian Bloomgren, current President & Chief Commercial Officer (CCO), will assume the role of President & CEO, and Ronda will serve as his executive advisor.

“Serving as CEO and President of Afaxys for the past 17 years has been an incredible privilege,” said Ronda Dean, CEO & Co-Founder of Afaxys. “From the very beginning, our mission has been grounded in reproductive justice and gender equity, and I am profoundly grateful to my colleagues, partners, and customers who have shared that passion and purpose with me. Afaxys has served millions of patients over the past 17 years, and I am confident that this impact will continue as Christian steps into the CEO role. He is an exceptional leader with strong strategic insights that will allow Afaxys to carry forward its legacy and shape a strong future for the company.”

Christian brings more than 25 years of experience in pharmaceutical, biotech, diagnostics, and medical devices, with strong expertise in women’s health. In his current role as President and CCO, Christian leads the strategy and execution of marketing, sales, and growth initiatives. As the newly appointed CEO, Christian shares the same mission and vision that have guided the success of Afaxys and brings a deep passion for continuing to drive the company forward.

“I am honored to step into the role of Afaxys’ CEO and am tremendously grateful for the support and collaboration I’ve experienced over the past two years working with Ronda and our exceptional team at Afaxys,” said Christian Bloomgren, current President & CCO of Afaxys. “As we move forward, my priority is to stay true to our mission, while positioning the company to achieve even greater growth and impact as leaders in public health.”

“On behalf of the Board, I want to thank Ronda for her transformative leadership in co-founding Afaxys and her incredible contributions to our mission and success over the years,” added Sarah Stoesz, Chair of the Board of Afaxys. “The selection of Ronda’s successor has been an important objective for the Board over the past few years, and we are equally excited to welcome Christian as our new CEO. The Board is confident he brings not only a deep understanding of our mission and vision, but also the drive and experience to guide Afaxys into its next chapter of growth and impact.”

About Afaxys

Afaxys, a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients.

The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys’ strategic goal of cost-conscious product commercialization. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization. For more information, visit www.afaxys.com.

Forward-Looking Statements

The statements in this press release that are not historical facts constitute “forward-looking statements” as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made.

Afaxys Media Contact
Green Room Communications
gr_afaxys@grcomms.com

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Join Today!

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.